Health · 16 views
Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b…
AI Summary
Subcutaneous administration of tarlatamab was well tolerated in patients with previously treated extensive‑stage small cell lung cancer. The phase 1b DeLLphi‑308 study reported preliminary antitumor activity for the drug.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastasesContinue reading
- Recommendations updated for management of anemia in chronic kidney diseaseContinue reading
- First dual-target high-intensity focused ultrasound procedure for people with advanced Parkinson's diseaseContinue reading
- IASLC tumor budding grade identifies high-risk patients with resected lung squamous cell carcinomaContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow